Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP.             STOCK EXCHANGE RELEASE       December 16, 2015 at 8.00 a.m.Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets ActBiotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) (“Biotie” or the “Company”) has on December 15, 2015 received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act from Mr. Samuel D. Isaly on behalf of himself and OrbiMed Advisors LLC, OrbiMed Capital GP V LLC and OrbiMed Private Investments V, LP as a result of the implementation of changes to the transparency directive in the Finnish Securities Market Act.According to the notification, the total number of Biotie shares owned directly or through financial instruments by Samuel D. Isaly and entities under his control was 11.54 per cent of Biotie’s total number of shares and voting rights on November 26,s 2015. Biotie’s registered total number of shares and voting rights amounting to 1,086,940,271 has been used in the calculation of percentages for the announcement.Total positions of Samuel D. Isaly and entities under his control subject to the notification:Notified details of the resulting situation on the date on which the threshold was crossed or reached:A: Shares and voting rightsFor further information on the ADSs representing the Company’s shares, the notification refers to the stock exchange release issued by the Company on June 11, 2015.B: Financial instruments according to SMA 9:6aFor further information on the warrants, the notification refers to the stock exchange release issued by the Company on April 23, 2015.Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:According to the notification, Samuel D. Isaly is the managing member of and owner of a controlling interest in OrbiMed Advisors LLC, which is the sole managing member of OrbiMed Capital GP V LLC. OrbiMed Capital GP V LLC is the general partner of OrbiMed Private Investments V, LP. Further, according to the notification neither Samuel D. Isaly nor any other entity under his control, other than OrbiMed Private Investments V, LP, holds any shares or financial instruments in the Company.In Turku, December 16, 2015Biotie Therapies Corp.Timo Veromaa
President and CEO
For further information, please contact:Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
DISTRIBUTION:NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com
HUG#1973901

Recommended
manufacturing image3